

DCVMN 2020

Pandemic Response: the critical role of DCVMs

Anita Zaidi

4 PILLARS GUIDE THE DEPLOYMENT OF FOUNDATION RESOURCES TO SUPPORT THE GLOBAL RESPONSE

COVID-19 Mission: Accelerate global efforts to curb the impact of the coronavirus pandemic by deploying foundation resources in support of four key pillars



Accelerate detection and suppression

Accelerate, fill gaps in, and inform global response¹ through partners with existing capacity for rapid action



Protect the most vulnerable

Rapidly strengthen capacity and coordination² to detect and respond to COVID-19 in target LMICs



Develop products for a sustained response

Leverage foundation's unique capacity to coordinate and fill gaps in COVID-19 product development³ while securing global access



Minimize societal and economic impact

Promote responses that balance health outcomes and economic recovery minimizing the negative impact on societies and individuals

1. Includes detection, testing, contact tracing, case isolation, etc. Also includes designing and implementing social distancing, personal & environmental hygiene, messaging/comms, etc.. 2. Includes disease surveillance, modeling & analytics, development of costed response plans, resource mobilization and alignment, etc.. 3. Includes R&D, product introduction (Dx, Rx, Vx), testing/scaling service delivery innovations, improving commodities availability/access, etc.

THE FOUNDATION HAS COMMITTED MORE THAN \$350M TO SUPPORT THE GLOBAL RESPONSE TO COVID-19

Foundation's total new commitments along our 4 pillars:

\$350M+

In addition to our \$350M+ in commitments, the foundation is...



Leveraging our \$2.5 billion Strategic Investment Fund to address market failures and incentivize private enterprise to develop affordable and accessible health products



Providing technical assistance, when requested, to a variety of multilateral organizations and government agencies to help accelerate the response

In addition to new funds committed to COVID-19 response, the foundation continuing to address our **program goals, maintaining commitments** to efforts in these areas, like malaria, TB, and global education

CATALYZING VACCINE DEVELOPMENT VIA THE COVAX PILLAR

Three pillars form
the ACT-
Accelerator

THERAPEUTICS



VACCINES
(COVAX)



DIAGNOSTICS



The COVAX pillar is a collaboration between the following organizations

CEPI

Development and manufacturing

Gavi
The Vaccine Alliance

Procurement and delivery targeting 2 billion doses
by the end of 2021


World Health
Organization

Policy, safety, regulation and allocation


WHAT WE ARE LEARNING THROUGH COVID-19

Nationalist procurement risk inhibiting LMIC access to lifesaving vaccines

Wealthy countries have funded R&D and secured access for domestic populations through bilateral deals...



... and without DCVMs, supply for LMICs would depend almost entirely on HIC willingness to provide leftover doses




[Source: BMGF - A three-part plan to eliminate COVID-19](#)

[Source: Financial Times](#) September 23, 2020

EQUITABLE DISTRIBUTION REDUCES OVERALL DEATHS

Applying influenza modeling methods to real life events highlights the risk of an HIC focused response


MODELED PERCENTAGE OF DEATHS (COMPARED TO NO VACCINE)



Source: Bill & Melinda Gates Foundation, 2020 Goalkeepers Report. Data from MOBS LAB, Northeastern University
www.gatesfoundation.org/goalkeepers/report/2020-report/#Northeastern_Modeling

DCVM EXPERTISE AND CAPACITIES PLAY A PIVOTAL ROLE IN ENABLING COVID-19 ACCESS





For example, global distribution of available excess fill/finish capacity highlights the potential for DCVM partnerships to ensure global supply and access beyond the US and Europe



BMGF is working with DCVMs to advance COVID-related goals as part of global effort to discover and manufacture vaccines

■ HOW DCVM'S ENABLE EQUITABLE ACCESS TO VACCINES

Key advantages of DCVM's:

	Quality/ Reliability	<ul style="list-style-type: none">• Proven track record of successful tech transfers and innovative approaches
	Cost/ Affordability	<ul style="list-style-type: none">• Ability to produce vaccines at a rate that meets the needs of suppliers and country specific requirements
	Reach	<ul style="list-style-type: none">• DCVM's reach Gavi countries and fill gaps in vaccine availability
	Commitment	<ul style="list-style-type: none">• A shared purpose ensures equitable access

■ DCVM'S ARE CRITICAL FOR GLOBAL HEALTH AND PANDEMIC RESPONSE



A close-up photograph of a young child with dark skin and short hair, wearing a white shirt, being held by an adult. A healthcare worker's hand is visible, holding a blue syringe and injecting a vaccine into the child's arm. The background is blurred, showing an outdoor setting with wooden structures. A semi-transparent dark grey box with a red square icon is overlaid in the top right corner, containing the text "THANK YOU".

 **THANK YOU**